ADDING MULTIMEDIA MyMD Pharmaceuticals® to Present Data on Oral TNF-a Inhibitor MYMD-1® at the British Society for Immunology (BSI) Congress 2022
CANNANNEW REPORT

– Preclinical and early clinical studies of MYMD-1®, an oral, small-molecule, selective TNF-α inhibitor, suggest future potential to disrupt the Rheumatoid Arthritis market – BALTIMORE–(BUSINESS WIRE)–MyMD Pharmaceuticals, Inc.® (Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage biopharmaceutical company developing groundbreaking therapies for the treatment of serious and debilitating autoimmune and inflammatory diseases, is presenting […]

Excerpt only …
READ MORE BELOW
Source : ADDING MULTIMEDIA MyMD Pharmaceuticals® to Present Data on Oral TNF-a Inhibitor MYMD-1® at the British Society for Immunology (BSI) Congress 2022

reposted by Cannabis News World